Press Releases

Date Title and Summary
Toggle Summary Capnia and Essentialis Announce Merger to Create Rare Disease Therapeutics Company
Combined Company to Focus on Advancing Novel, Late-Stage Asset for the Treatment of Prader-Willi Syndrome, a Devastating, Orphan Disease  Enrollment in a Phase II/III Clinical Trial Expected to Begin in Second Half of 2017 $8 Million Concurrent Financing; Sufficient to Fund Development Plan Through
Toggle Summary Capnia Reports Third Quarter 2016 Financial Results
REDWOOD CITY, Calif. , Nov. 14, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced financial results for the third quarter ended
Toggle Summary Capnia to Present at Upcoming Investor Conferences
REDWOOD CITY, Calif. , Sept. 06, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar , M.D., Chief Executive
Toggle Summary Capnia Reports Second Quarter 2016 Financial Results
Strong Consumer Feedback from Pilot Serenz Sales in the UK REDWOOD CITY, Calif. , Aug. 12, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today
Toggle Summary Capnia Announces Private Placement of Up to $13.8 Million of Convertible Preferred Stock
REDWOOD CITY, Calif. , June 29, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that it has entered into an agreement with a
Toggle Summary Capnia Expands Commercial Launch of Serenz® Allergy Relief to Ireland
- Pilot Program to Include 25 Community Pharmacies - REDWOOD CITY, Calif. , June 15, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today
Toggle Summary Capnia Announces Exclusive Distribution Agreement for CoSense® End-Tidal Carbon Monoxide Monitor in India
-Agreement represents continued expansion of CoSense outside the US- REDWOOD CITY, Calif. , June 07, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical
Toggle Summary Capnia to Present at 2016 Marcum MicroCap Conference
REDWOOD CITY, Calif. , May 25, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar , M.D., Chief Executive
Toggle Summary Capnia Reports First Quarter 2016 Financial Results
-Early 2016 Marked by Commencement of Serenz® Sales to European Pharmacies and New Global Distribution Agreements for CoSense® - REDWOOD CITY, Calif. , May 10, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative
Toggle Summary Capnia to Present at the Joseph Gunnar “Pioneers 2016” Conference
REDWOOD CITY, Calif. , April 27, 2016 (GLOBE NEWSWIRE) -- Capnia, Inc. (NASDAQ:CAPN), a diversified healthcare company that develops and commercializes innovative diagnostics, devices and therapeutics addressing unmet medical needs, today announced that Anish Bhatnagar , M.D., Chief Executive